A part of the data were presented at the 19th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), Cincinnati, OH, U.S.A., September 1997, in the form of an abstract.
Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women†
Article first published online: 1 SEP 1999
Copyright © 1999 ASBMR
Journal of Bone and Mineral Research
Volume 14, Issue 9, pages 1622–1627, September 1999
How to Cite
Ravn, P., Cizza, G., Bjarnason, N. H., Thompson, D., Daley, M., Wasnich, R. D., Mcclung, M., Hosking, D., Yates, A. J. and Christiansen, C. (1999), Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women. J Bone Miner Res, 14: 1622–1627. doi: 10.1359/jbmr.19188.8.131.522
- Issue published online: 2 DEC 2009
- Article first published online: 1 SEP 1999
- Manuscript Accepted: 19 MAR 1999
- Manuscript Revised: 19 FEB 1999
- Manuscript Received: 5 OCT 1998
Thinness (low percentage of body fat, low body mass index [BMI], or low body weight) was evaluated as a risk factor for low bone mineral density (BMD) or increased bone loss in a randomized trial of alendronate for prevention of osteoporosis in recently postmenopausal women with normal bone mass (n = 1609). The 2-year data from the placebo group were used (n = 417). Percentage of body fat, BMI, and body weight were correlated with baseline BMD (r = −0.13 to −0.43, p < 0.01) and 2-year bone loss (r = −0.14 to −0.19, p < 0.01). Women in the lowest tertiles of percentage of body fat or BMI had up to 12% lower BMD at baseline and a more than 2-fold higher 2-year bone loss as compared with women in the highest tertiles (p ≤ 0.004). Women with a lower percentage of body fat or BMI had higher baseline levels of urine N-telopeptide cross-links (r = −0.24 to −0.31, p < 0.0001) and serum osteocalcin (r = −0.12 to −0.15, p < 0.01). To determine if the magnitude of treatment effect of alendronate was dependent on these risk factors, the group treated with 5 mg of alendronate was included (n = 403). There were no associations between fat mass parameters and response to alendronate treatment, which indicated that risk of low bone mass and increased bone loss caused by thinness could be compensated by alendronate treatment. In conclusion, thinness is an important risk factor for low bone mass and increased bone loss in postmenopausal women. Because the response to alendronate treatment is independent of fat mass parameters, prevention of postmenopausal osteoporosis can be equally achieved in thinner and heavier women.